Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Preferred Stock Liabilities (2019)

Beam Therapeutics (BEAM) has disclosed Preferred Stock Liabilities for 1 consecutive years, with $302.0 million as the latest value for Q4 2019.

  • On a quarterly basis, Preferred Stock Liabilities changed N/A to $302.0 million in Q4 2019 year-over-year; TTM through Dec 2019 was $302.0 million, a N/A change, with the full-year FY2019 number at $302.0 million, changed N/A from a year prior.
  • Preferred Stock Liabilities was $302.0 million for Q4 2019 at Beam Therapeutics, up from $298.8 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $302.0 million in Q4 2019 to a low of $292.3 million in Q1 2019.